1. Home
  2. KNF vs IDYA Comparison

KNF vs IDYA Comparison

Compare KNF & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knife Riv Holding Co.

KNF

Knife Riv Holding Co.

HOLD

Current Price

$64.39

Market Cap

3.7B

Sector

N/A

ML Signal

HOLD

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$40.16

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNF
IDYA
Founded
1917
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.6B
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
KNF
IDYA
Price
$64.39
$40.16
Analyst Decision
Buy
Strong Buy
Analyst Count
8
16
Target Price
$97.25
$52.86
AVG Volume (30 Days)
899.1K
682.5K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.90
EPS
N/A
N/A
Revenue
$3,146,012,000.00
$218,710,000.00
Revenue This Year
$8.93
N/A
Revenue Next Year
$5.28
$201.05
P/E Ratio
N/A
N/A
Revenue Growth
8.52
3024.43
52 Week Low
$58.72
$23.23
52 Week High
$96.28
$42.68

Technical Indicators

Market Signals
Indicator
KNF
IDYA
Relative Strength Index (RSI) 38.35 64.18
Support Level N/A $33.23
Resistance Level $80.09 N/A
Average True Range (ATR) 2.28 1.29
MACD 0.42 0.37
Stochastic Oscillator 35.80 73.15

Price Performance

Historical Comparison
KNF
IDYA

About KNF Knife Riv Holding Co.

Knife River Corp is a people-first construction materials and contracting services company. It provides construction materials and contracting services to build safe roads, bridges, airport runways, and other critical infrastructure needs that connect people. The group is a provider of crushed stone, sand, and gravel in the United States. It operates through four reportable segments: West, Mountain, Central, and Energy Services.

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Share on Social Networks: